Investor Area

Home / Investor Area / Company Snapshot

Company Snapshot

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead product, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). In October 2019 the US FDA approved SCENESSE® (afamelanotide) to increase pain free light exposure in adult patients with a history of phototoxic reactions from EPP. More information on EPP can be found at http://www.epp.care.

Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore. 

Facts
ASX Listed
2001
Shares on Issue
49,410,338
Conditional performance rights
138,333
52 week price range (27/08/20)
$12.92 – $45.88
Market cap (27/08/20)
A$1,094m
Locations
Melbourne, Australia
Company headquarters
Zug, Switzerland
Swiss operational office
Leatherhead, UK
UK operational office
Singapore
Asian operational office
Burlingame, US
US operational office
www.clinuvel.com
Stock listings
ASX
CUV
Xetra-DAX
UR9
Level 1 ADR
CLVLY
Key financial statistics FY June 2020
Total revenue
A$33.9m
Net profit
A$16.6m
Net cash increase
A$11.8m
Cash
A$66.7m
Total assets
A$81.5m
Equity
A$73.7m
Products
SCENESSE® (afamelanotide 16mg implant)
First-in-class photoprotective and repigmentation drug with EMA and US FDA approvals for rare disease EPP. Phase IIb trial completed in Singapore for vitiligo.
CUV9900
Alpha-Melanocyte Stimulating Hormone
(alpha-MSH) analogues in early development.
VLRX001
PRÉNUMBRA®
PRÉNUMBRA® is a liquid (non-solid) injectable formulation of afamelanotide designed for administration by a healthcare professional and intended to provide a flexible dose of afamelanotide, a synthetic analogue of natural α-melanocyte stimulating hormone.
People
Willem Blijdorp
Non-Executive Chair
Dr Philippe Wolgen
CEO, Director
Brenda Shanahan
Non-Executive Director
Dr Karen Agersborg
Non-Executive Director
Susan Smith
Non-Executive Director
Professor Jeffrey V. Rosenfeld
Non-Executive Director
Dr Dennis Wright
Acting Chief Scientific Officer
Darren Keamy
CFO, Company Secretary

Last Updated: 27 August 2020